Ọnwụnwa ụlọọgwụ ga-aga nke ọma maka iji ọbara eriri afọ mmadụ gwọọ ọrịa strok siri ike.

Ụlọ ọrụ ọgwụgwọ ọbara na Southern California StemCyte Inc. na-akpọsa nsonaazụ mbido ga-aga nke ọma maka usoro nke mbụ nke ụlọ ọrụ ụlọ ọrụ maka ịgwọ nnukwu ọrịa strok site na iji monocytes sitere na allogeneic umbilical cord blood (hUCB). Ebipụtara nchoputa nke ọmụmụ nke Oge I na Mgbanwe Cell (CLL) na Disemba 2021.

Print Friendly, PDF & Email

Emere ọmụmụ ihe nke mbụ na ndị ọrịa dị afọ 45-80 bụ ndị kwadoro nnukwu ọrịa strok ischemic. E nwetara ọbara eriri afọ site na nchịkọta ọbara ọhaneze StemCyte dabere na ụdị ọbara ABO/Rh, egwuregwu Human Leukocyte Antigen (HLA) nke> 4/6, na mkpụrụ ndụ nke mkpokọta mononuclear cell (MNC) ọnụ nke 0.5-5 x. 107 sel / n'arọ. Na mgbakwunye, a na-enye doses mannitol anọ (4) 100 ml n'ime intravenously nkeji iri atọ na-esochi ntụgharị ọbara eriri afọ na oge awa 30 ọ bụla gachara.

Nsonaazụ bụ isi bụ ọnụọgụ ndị ọrịa butere graft versus host disease (GVHD) n'ime 100 ụbọchị ka mmịnye gasịrị. Nsonaazụ nke abụọ bụ mgbanwe na National Institutes of Health Stroke Scale (NIHSS), Barthel index, na Berg Balance Scale scores. N'otu oge, onye ọrịa dị afọ 46 nwere akụkọ ihe mere eme nke ọbara mgbali elu na hemodialysis maka ọrịa akụrụ na njedebe nke njedebe ka a na-agwọ ya na-eji hUCB nwere otu ABO/Rh, egwuregwu 6/6 HLA, na ọnụ ọgụgụ MNC nke 2.63 x 108. sel / kg. Onye ọrịa ahụ egosighi ihe omume ọjọọ ma ọ bụ GVHD n'oge ọmụmụ ọnwa 12. Akara NIHSS ya belatara site na 9 ruo 1; Ọnụ ọgụgụ Berg Balance Scale mụbara site na 0 ruo 48, na akara Barthel index mụbara site na 0 ruo 90. Nnyocha mbụ a gosiri na onye okenye nwere ọrịa hemiplegia n'ihi ọrịa strok ischemic gbakere kpamkpam n'ime ọnwa 12 mgbe ọ nwetasịrị ọgwụgwọ allogeneic UCB.

"Anyị nwere nnọọ obi ụtọ na nsonaazụ ụlọ ọgwụ na-aga nke ọma nke ọmụmụ StemCyte's Phase I," StemCyte President na Onye isi oche Jonas Wang, PhD kwuru. "Ebe nnukwu ọrịa strok bụ nke abụọ na nke atọ na-ebute ọnwụ na nkwarụ, n'otu n'otu, n'ụwa nile, nsonaazụ a pụtara ìhè dịka ọ na-atụghị anya ya." Ihe dị ka 30%-35% nke ndị na-arịa ọrịa strok na-anwụ na ihe fọrọ nke nta ka ọ bụrụ 75% nke ndị lanarịrịnụ na-enwe nkwarụ na-adịgide adịgide. Ọgwụgwọ ugbu a n'oge nnukwu oge gụnyere iji thrombolytic, anticoagulant, na antiplatelet. Otú ọ dị, iji ihe ndị dị otú ahụ eme ihe na-eme ka ọbara ọgbụgba na-abawanye site na 15%-20%.

Mkpụrụ ndụ akwara ọbara na-amụba n'ime mkpụrụ ndụ akwara, a chọpụtakwara na ha na-arụ ọrụ nke ọma n'ịgwọ ọtụtụ ọrịa neurodegenerative. N'ime ọrịa strok nke ụbụrụ, nchịkwa intravenous nke UCB na MNC nwere ike iweghachi ikike mmega ahụ yana inye mmetụta neuroprotective dị ka egosipụtara site n'ibelata ngosipụta nke nrịbama mkpali dị ka TNF-alpha, IL-1β na IL-2.

Print Friendly, PDF & Email

Akụkọ ndi ozo

Banyere chepụtara

nchịkọta akụkọ

Onye nchịkọta akụkọ nke eTurboNew bụ Linda Hohnholz. Ọ dabere na eTN HQ na Honolulu, Hawaii.

Ahapụ a Comment